Completed PHASE4 INTERVENTIONAL 2-arm NCT05238012

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME)

A 24-week, Multi-center, Randomized, Open-Label Clinical Trial to Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME Study)

Sponsor: AstraZeneca

Conditions Metabolism Disorder, Glucose Metabolism Disorder, Lipid

Interventions Atorvastatin Calcium Tablets Xuezhikang Capsule

Updated 5 times since 2022 Last updated: May 19, 2024 Started: Aug 2, 2022 Primary completion: Apr 2, 2024 Completion: Apr 2, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Metabolism Disorder, Glucose and Metabolism Disorder, Lipid and is currently completed. AstraZeneca leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2024 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Mar 2024 — Jun 2024 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Mar 2022 — Mar 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Heart Health Research Center

Data source: Heart Health Research Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China